Soslan Rolanovich Urtaev
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Soslan Rolanovich Urtaev has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Aleksandr Igorevich Khalimon
Department of Nuclear Medicine, Moscow Oncology Research Institute, FSBI "National Medical Research Radiological Centre" of the Ministry of Health of the Russian Federation, Moscow, Russia
2 shared publications Aleksei Victorovich Leontev
Department of Nuclear Medicine, P. Hertsen Moscow Oncology Research Institute - The Branch of the FSBI "National Medical Research Radiological Centre" of the Ministry of Health of the Russian Federation, Moscow, Russia
2 shared publications- Anastasia Igorevna Nikiforuk
Department of Nuclear Medicine, Moscow Oncology Research Institute, FSBI "National Medical Research Radiological Centre" of the Ministry of Health of the Russian Federation, Moscow, Russia
2 shared publications - Andrei Dmitrievich Kaprin
National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Koroleva St. 4, 249036 Obninsk, Russia
2 shared publications - Daria Yurevna Khodakova
Department of Nuclear Medicine, Moscow Oncology Research Institute, FSBI "National Medical Research Radiological Centre" of the Ministry of Health of the Russian Federation, Moscow, Russia
2 shared publications - Gulnara Faridovna Khamadeeva
Department of Nuclear Medicine, Moscow Oncology Research Institute, FSBI "National Medical Research Radiological Centre" of the Ministry of Health of the Russian Federation, Moscow, Russia
2 shared publications
Latest Publications
- Open Access
- 23 October 2026
- Published by Elsevier in The EANM Journal
- Vol. 5
Imaging more, changing nothing: Are there predictors of unchanged management after [18F]PSMA-1007 PET/CT in primary staging of high-risk prostate cancer?
- 23 October 2026
- Published by Elsevier in The EANM Journal
- Vol. 5
Open AccessImaging more, changing nothing: Are there predictors of unchanged management after [18F]PSMA-1007 PET/CT in primary staging of high-risk prostate cancer?
- Open Access
- 10 April 2026
- Published by Springer Nature in Cancer Imaging
- Vol. 26 (1)
[¹⁸F]PSMA-1007 and [¹⁸F]FDG PET/CT in patients with metastatic triple-negative breast cancer: a prospective head-to-head comparison and assessment of PSMA-targeted radioligand therapy applicability
Triple-negative breast cancer (TNBC) is an aggressive molecular subtype of breast cancer with limited treatment approaches. Prostate-specific membrane antigen (PSMA), widely applied as a target for molecular imaging and radioligand therapy of prostate cancer, demonstrates the highest expression in TNBC across all molecular subtypes of breast cancer, and represents a promising target for imaging and treatment of TNBC patients. This prospective study included 20 patients with metastatic TNBC who underwent both [¹⁸F]PSMA-1007 and [¹⁸F]FDG PET/CT. Qualitative and quantitative image analysis was performed to determine the uptake predominance of one of the tracers and the added value of the diagnostic CT, as well as to assess the potential applicability of PSMA-targeted radioligand therapy (PSMA-RLT). A total of 229 lesions were identified using both [¹⁸F]PSMA-1007 and [¹⁸F]FDG PET/CT. Concordant and discordant lesions were observed for both tracers, with a greater number of discordant lesions identified by [¹⁸F]PSMA-1007. [¹⁸F]FDG demonstrated higher uptake in TNBC lesions. An exception was observed in lung lesions, where no significant difference was found between tracers. The application of diagnostic CT revealed additional TNBC lesions that were not identified by PET, for each tracer. None of the patients demonstrated a [¹⁸F]PSMA-1007 uptake level sufficient for potential PSMA-RLT application when a lesional SUV-based threshold was used. Despite detectable [¹⁸F]PSMA-1007 uptake in TNBC lesions, [¹⁸F]FDG uptake was generally higher. Furthermore, the diagnostic CT can identify additional PET-negative lesions. Although PSMA expression is confirmed in TNBC, it may be insufficient to provide potential benefit from PSMA-RLT for this patient group.
- 10 April 2026
- Published by Springer Nature in Cancer Imaging
- Vol. 26 (1)
Open Access[¹⁸F]PSMA-1007 and [¹⁸F]FDG PET/CT in patients with metastatic triple-negative breast cancer: a prospective head-to-head comparison and assessment of PSMA-targeted radioligand therapy applicability
Triple-negative breast cancer (TNBC) is an aggressive molecular subtype of breast cancer with limited treatment approaches. Prostate-specific membrane antigen (PSMA), widely applied as a target for molecular imaging and radioligand therapy of prostate cancer, demonstrates the highest expression in TNBC across all molecular subtypes of breast cancer, and represents a promising target for imaging and treatment of TNBC patients. This prospective study included 20 patients with metastatic TNBC who underwent both [¹⁸F]PSMA-1007 and [¹⁸F]FDG PET/CT. Qualitative and quantitative image analysis was performed to determine the uptake predominance of one of the tracers and the added value of the diagnostic CT, as well as to assess the potential applicability of PSMA-targeted radioligand therapy (PSMA-RLT). A total of 229 lesions were identified using both [¹⁸F]PSMA-1007 and [¹⁸F]FDG PET/CT. Concordant and discordant lesions were observed for both tracers, with a greater number of discordant lesions identified by [¹⁸F]PSMA-1007. [¹⁸F]FDG demonstrated higher uptake in TNBC lesions. An exception was observed in lung lesions, where no significant difference was found between tracers. The application of diagnostic CT revealed additional TNBC lesions that were not identified by PET, for each tracer. None of the patients demonstrated a [¹⁸F]PSMA-1007 uptake level sufficient for potential PSMA-RLT application when a lesional SUV-based threshold was used. Despite detectable [¹⁸F]PSMA-1007 uptake in TNBC lesions, [¹⁸F]FDG uptake was generally higher. Furthermore, the diagnostic CT can identify additional PET-negative lesions. Although PSMA expression is confirmed in TNBC, it may be insufficient to provide potential benefit from PSMA-RLT for this patient group.
- 1 January 2022
- Published by Media Sphere Publishing Group in Russian Journal of Clinical Dermatology and Venereology
- Vol. 21 (2)
Cutaneous manifestations of endocrine disorders
- 1 January 2022
- Published by Media Sphere Publishing Group in Russian Journal of Clinical Dermatology and Venereology
- Vol. 21 (2)
Cutaneous manifestations of endocrine disorders